Cadrenal TherapeuticsCVKD
13F holders, Q2 2025 (June 30)14holders +1
4new positions
3sold out
$12.05avg. 13F price*
At the end of Q2 2025, 14 institutions reported holding Cadrenal Therapeutics Inc. (CVKD) in their 13F filings, up 1 from Q1 2025. 4 opened new positions and 3 sold out. The largest holders were Vanguard Group Inc. ($586K), Geode Capital Management, LLC ($153K) and BlackRock, Inc. ($40K).
- Company
- Cadrenal Therapeutics Inc.
- CUSIP
- 127636207
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $65K |
| Exits | 3 | $3K |
All 13F filers, Q1 2025 → Q2 2025: 9,024 shares bought and 9,981 shares sold, net −957 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 14 holders
| Vanguard Group Inc. | 0.00% | Add +6.5% | 48,595 | $586K |
| Geode Capital Management, LLC | 0.00% | Add +5.2% | 12,710 | $153K |
| BlackRock, Inc. | 0.00% | New | 3,282 | $40K |
| Raymond James Financial Inc. | 0.00% | New | 1,917 | $23K |
| Osaic Holdings, Inc. | 0.00% | Reduce -66.7% | 500 | $6K |
| Morgan Stanley | 0.00% | Reduce -62.0% | 430 | $5K |
| UBS Group AG | 0.00% | Reduce -96.1% | 326 | $4K |
| Jones Financial Companies LLLP | 0.00% | No change | 172 | $2K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 136 | $2K |
| Wells Fargo & Company | 0.00% | No change | 100 | $1K |
| Harbour Investments, Inc. | 0.00% | New | 100 | $1K |
| Archer Investment Corp | 0.00% | No change | 35 | $422 |
| IFP Advisors, Inc | 0.00% | No change | 30 | $362 |
| Bank of America Corp. | 0.00% | Add +27.3% | 14 | $169 |
"% of holder's portfolio" is CVKD's weight in each manager's 13F, not the share of Cadrenal Therapeutics Inc. the manager owns.